Gilead's Acquisitions Turn Near-Term Losses Into a Pipeline Bet

Gilead's second-quarter 2026 income statement looks weak at first glance, but the main cause was a deliberate expansion of its drug pipeline. The company recorded $11.2 billion of acquired in-process research and development expense, primarily tied to the Arcellx, Tubulis and Ouro Medicines acquisitions.

That accounting charge pushed Gilead to a GAAP loss even as product sales rose 8% to $7.6 billion. Product sales excluding Veklury increased 10%, led by HIV products, Trodelvy and Livdelzi. HIV sales reached about $5.7 billion, up 12%.

The acquisitions changed the timing and risk of Gilead's earnings without changing the fact that the acquired medicines still must succeed clinically. Acquired research expense is recognized immediately, while potential revenue may arrive years later or not at all.

Gilead's established HIV franchise continues to generate the cash needed to support that strategy. The company also produced substantial trailing free cash flow and maintained its dividend, giving it more flexibility than an early-stage biotechnology company. Still, cash spent on acquisitions competes with buybacks, debt reduction and other pipeline investments.

The strategic goal is diversification. Arcellx adds cell-therapy exposure, Tubulis brings antibody-drug conjugate technology, and Ouro adds autoimmune programs. Each area could expand Gilead's growth options, but each carries trial, regulatory and commercial risk.

Investors should avoid treating the $11.2 billion charge as either a recurring operating expense or proof of future value. The useful questions are whether acquired programs reach clinical milestones, whether Gilead can integrate the teams and whether eventual products generate returns above the acquisition cost.

Management's full-year GAAP outlook reflected the acquired research charges, while the underlying product business remained profitable on a non-GAAP basis. That gap is a reminder that adjusted earnings can clarify ongoing operations but cannot make the capital spent on acquisitions disappear.

Gilead has exchanged near-term accounting earnings and cash for a broader pipeline. The investment case now depends on scientific execution as much as on the durability of HIV cash flows.